# Tempus AI's first quarterly profit of $5.6m came from below the operating line — a $75.9m operating loss met $102.8m of other income, mostly marks on listed shares; for the half year that line is only $75.0m

![Tempus AI's first quarterly profit of $5.6m came from below the operating line — a $75.9m operating loss met $102.8m of other income, mostly marks on listed shares; for the half year that line is only $75.0m](https://aiswingx.com/static/covers/tem-2026q2_cover.jpg?v=1790083260)

**Q2 2026 10-Q: revenue $382.5m (+22%), operating loss $75.9m (from $61.8m), net income $5.6m. The profit rests on other income of $102.8m, whose source is $216.4m of publicly traded shares remeasured every quarter. The quarter also carries an $11.6m loss on debt extinguishment and $2.9m of equity-method losses. First-half operating cash flow was −$80.8m, receivables of $360.9m equal 94% of quarterly revenue, and first-half stock-based compensation of $106.8m is 15% of revenue**

Tempus AI (TEM) reported second-quarter 2026 revenue of $382.5m, up 22%, and swung from a $42.8m net loss a year earlier to **net income of $5.6m**. Reading down the income statement in the 10-Q filed on July 24 shows where that profit came from: the operating result is a loss of $75.9m, and the line beneath it, other income net, is $102.8m.

- 종목: TEM (Tempus AI)
- 분기: 2026Q2 · 10-Q
- 작성: 2026-09-22 13:21 UTC · 업데이트: 2026-09-22 14:29 UTC
- 원문: https://aiswingx.com/p/tem-2026q2

## 숫자 하나
Q2 operating loss $75,913k → interest income $3,897k, interest expense −$10,283k, loss on debt extinguishment −$11,643k, other income net +$102,757k → pre-tax income $8,815k, tax −$309k, equity-method losses −$2,864k → net income $5,642k. First-half other income $75,048k (Q2 alone $102,757k, so Q1 was negative); first-half gain on marketable equity securities $66,166k (non-cash). Receivables $360.9m = 94% of quarterly revenue.

## 비유 하나
(구독자 전용)

## 출처 하나
Tempus AI Form 10-Q for Q2 2026 (as of June 30): statement of operations (operating loss, other income, loss on debt extinguishment, equity-method losses), cash-flow statement (gain on marketable equity securities, stock-based compensation), Note 15 Fair Value Measurements and Marketable Equity Securities, balance sheet (receivables, cash) and the revenue and liquidity sections of MD&A

## 다음 분기에 볼 것
(구독자 전용)

---

## What happened

Tempus AI (TEM) sequences tumours for cancer patients and licenses the resulting data to pharmaceutical companies and researchers.

Its quarterly report (10-Q) for Q2 2026 shows revenue of **$382.5m**, up 22% from $314.6m: genomics $289.3m and data and applications $93.2m ($72.8m a year earlier). Total cost and operating expenses were $458.4m, leaving an **operating loss of $75.9m**, wider than the $61.8m of a year earlier.

The lines below tell the quarter's story: interest income $3.9m, interest expense −$10.3m, a **loss on debt extinguishment of −$11.6m**, and **other income, net of +$102.8m**. That produces pre-tax income of $8.8m; after tax of −$0.3m and equity-method losses of −$2.9m, **net income is $5.6m**. A year earlier the same quarter showed a $42.8m net loss.

---

(End of free preview. What the numbers mean, why it matters, company context, the next-quarter checklist and the arithmetic are available to subscribers — https://aiswingx.com/pricing)

## 관련 뉴스
- [Tempus AI: High Risk, But With A Great Cause (NASDAQ:TEM)](https://news.google.com/rss/articles/CBMiiwFBVV95cUxNUTdSUHlqUTFhQ2NRNFJ2ZWVwQ1VZRmtfSXRYdkd5SVIxYmNtSEpIR0FXUUhQMDFObkJJVld4QWlwekswLWVBTExndWhaVTNuXzBxWE1Od1l1aHpCcDhhX2xlVElOVC11VDZvRlJBMnQ4NGxnM2FLSG9RSU1XTHppTVc2SVV4MEp5M2pj?oc=5) — Seeking Alpha
- [Tempus AI (NASDAQ:TEM) Upgraded by The Goldman Sachs Group to Hold Rating](https://news.google.com/rss/articles/CBMizgFBVV95cUxQQS1KR2wtLTJ2X1FIUEptWEJQUXNmSUhDWjNmRkhVQnN5NWJ1RkRLMDNsbDBIbGRCVkZOTEE0b3pMVDVEeUs4aU8tbUpXMlBRNlJTV09VVElieGdTUm5UNGZhNlpSZy1XMjVqbUJOOUZuMUdiNkQ2SVQ5ZWlDcmxYWXpqZXZwempiMUNkbVZyT3kxdTB3UXpHajBZak1kY2NUbTFlU3cwbk1PSTZ2cU5hbjVDV1c0SlRsTW9YZERMTTRzbjRLZUtUUFNtTmtMUQ?oc=5) — MarketBeat
- [Tempus AI raises full-year outlook after 22% re...](https://news.google.com/rss/articles/CBMihgFBVV95cUxNSzJuSXJBNi1NTjBrMm84TTVxUTVtcEpmbW5ZeVdJSmFIOGNZYlJjZk51dlY1RUtoVWpvUG02UE1wNXRsVXBxV2RDVUFEd2tJSWxhTi1qNTBjc1h1dGlJTWdic1N6MWprZ3pDWEQ3Qk9OeTZYbE5oQTdlNEt1WTdrdm10dkRjdw?oc=5) — pluang.com
- [Tempus AI: Data And Applications Will Unlock More Upside (NASDAQ:TEM)](https://news.google.com/rss/articles/CBMinwFBVV95cUxQbllwQkpnTklKRjQ1RDJScnl6ekoybUJuSmFDRk1LYjNTS2hHbnRLa2cxWkE4d0lQVDJ6Wjd3SkVJZC1kZVJ2eGplYkxtV2dGeGxoUXJFTzdWd2lXSVBpOUxUMDNBbGlOUXVhUUQtZlRncV83MXFUWVZIelNpNVA3UGEtY1R5YXR3TjgyRW54T3VaeEV2UVV6NUVBZ3NKSUU?oc=5) — Seeking Alpha

## FAQ

**Q. Is the profit not real?**

Net income of $5,642k for Q2 2026 is what the income statement reports. This article shows which lines produced it: an operating loss of $75,913k, then other income net of $102,757k, and in the cash-flow statement the company reverses a $66,166k first-half gain on marketable equity securities as a non-cash item.

**Q. Does other income recur at this level?**

The filing's own numbers say no. Other income was $102,757k in Q2 but $75,048k for the first half, which means the line was negative in Q1. The assets being marked are publicly traded shares, so the direction changes with their prices.

**Q. How is the operating business doing?**

Revenue was $382.5m (+22%), of which data and applications contributed $93.2m ($72.8m a year earlier) and genomics $289.3m. Total cost and operating expenses were $458.4m, more than revenue. First-half operating cash flow was −$80.8m.

**Q. Where can I verify these numbers?**

On SEC EDGAR: the Q2 2026 Form 10-Q (accession 0001193125-26-326090) — 'Loss from operations', 'Other income, net' and 'Loss on debt extinguishment' in the statement of operations, 'Gain on marketable equity securities' in the cash-flow statement, Note 15 Fair Value Measurements and Marketable Equity Securities, and the liquidity section of MD&A.